Arrowhead Pharmaceuticals Closes $45 Million Private Offering

齐欢畅2

August 12, 2016Arrowhead Pharmaceuticals Closes $45 Million Private OfferingPASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it closeda previously announced private offering with a select group of investors including Orbimed, RA Capital Management,Perceptive Advisors, RTW Investments and certain other institutional investors. Gross proceeds were $45 million.Approximately 7.63 million shares of common stock were issued at a price of $5.90 per share.Cantor Fitzgerald & Co. acted as sole placement agent for the private offering. Trout Capital LLC and Chardan CapitalMarkets LLC acted as financial advisors.This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there beany offer, solicitation or sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.The securities sold in the private placement have not been registered under the Securities Act of 1933, as amended (the"Securities Act"), or any state or other jurisdiction's securities laws, and may not be offered or sold in the United Statesabsent registration or an applicable exemption from the registration requirements of the Securities Act and applicable stateor other jurisdictions' securities laws. The Company has agreed to file a registration statement with the Securities andExchange Commission registering the resale of the shares of common stock issued and sold in the private placement.About Arrowhead PharmaceuticalsArrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNAinterference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is amechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of aspecific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing. The company'spipeline includes ARC-520 and ARC-521 for chronic hepatitis B virus infection, ARC-AAT for liver disease associated withalpha-1 antitrypsin deficiency, ARC-F12 for hereditary angioedema and thromboembolic disorders, ARC-LPA forcardiovascular disease, and ARC-HIF2 for renal cell carcinoma.

东霸天

8月12日，2016Arrowhead制药关闭$ 4500万私人OfferingPASADENA， - （美国商业资讯） - 箭头制药公司（纳斯达克股票代码：ARWR）今天宣布，它以前closeda宣布与一组选定的投资者，包括沃脉德资本，资本RA私募发行管理顾问感知，RTW投资和其他一些机构投资者。所得款项总额为$ 45 million.Approximately 763万普通股分别以$ 5.90的价格发行每share.Cantor菲茨杰拉德公司担任独家配售代理为公开发行。特劳特资本公司和Chardan CapitalMarkets有限责任公司担任财务advisors.This新闻稿不构成出售要约或要约的招揽购买这些证券，也不得有豆腥味提供在任何司法管辖区邀请或销售这些证券，其中这样的要约，招揽或销售将是私募形式尚未根据1933年证券法，修订（以下简称“证券法”）或任何州或其他司法管辖区的证券法unlawful.The证券​​，不得提呈发售或出售在美国Statesabsent注册或证券法和适用的stateor其他司法管辖区的证券法的登记要求的适当豁免。本公司已同意提交登记声明向美国证券委员会andExchange注册，导致them.Using发行及私人placement.About箭头PharmaceuticalsArrowhead药品销售的沉默基因开发了治疗难治性疾病的药物的普通股股份的转售广泛的RNA化学成分和快捷的交货方式的组合，箭头疗法触发RNAinterference机制，诱导靶基因的快速，深，耐用击倒。 RNA干扰，或RNAi，是amechanism存在于活抑制特定基因的表达，从而影响生产非特异性蛋白质的细胞。箭头的基于RNAi的疗法利用基因沉默的这种自然的途径。所述company'spipeline包括ARC-520和ARC-521用于治疗慢性乙肝病毒感染，ARC-AAT肝病相关withalpha-1抗胰蛋白酶缺乏症，ARC-F12为遗传性血管水肿和血栓栓塞性病症，ARC-LPA forcardiovascular疾病，和ARC -HIF2用于肾细胞癌。